BioCentury This Week

Author: BioCentury

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Be a guest on this podcast

Language: en-us

Genres: Business, Life Sciences, Science

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Get all podcast data

Listen Now...

Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules
Episode 348
Monday, 2 February, 2026

RNAi and exon-skipping therapies headline the list of regulatory and pivotal data catalysts in 2026, while new lipid-lowering mechanisms, modalities, and precision medicines define cardiovascular disease catalysts this year. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the most important milestones of the year in new modalities, CV and renal diseases.The analysts also discuss a new regulation in China introducing orphan drug exclusivity that could incentivize development of rare disease therapies.Dig into the BioCentury’s catalyst picks and the new China policy below• 2026 Catalysts: The rise of RNAi• 2026 Cardiovascular Catalysts: Lp(a) on the Horizon• 2026 Obesity Catalysts: Launches, readouts and challengers• 2026 Catalysts: Breakthrough progress in renal disease• AZ signals all-in on obesity via CSPC deal for $1.2B up front• China’s orphan drug exclusivity could bolster market, incentivize developmentView full story: https://www.biocentury.com/article/65828600:00 - Introduction02:28 - RNAi and Antisense Therapies06:37 - Neuromuscular and Musculoskeletal10:33 - Renal Disease Catalysts22:26 - China's New Orphan RulesTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text